The last few weekends have been roiled by headlines. Here's why we took a different direction on this medical stock this week ...

The stock's fall snapped a three-day winning streak.

Chairman and CEO of Abbott Laboratories (NYSE:ABT), recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Ford ...

His fears were that Abbott (NYSE:ABT) might pull the product entirely rather than risk further lawsuits—just like Johnson & ...

North Chicago, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells healthcare products. Valued at $229.1 billion by market ... covering ABT stock, the ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS increase.

Also Read: Abbott Laboratories Recalls Some Sensors For ... among insulin-intensive patients, expanding market share with the Libre system's insulin pump connectivity, and tapping into the ...

Healthcare product and device company Abbott Laboratories (NYSE: ABT) met Wall Street’s revenue expectations in Q4 CY2024, ...